The researchers have discovered a protein called AKAP4 that circulates in the blood and appears to be more accurate than the current method of low-dose CT scans for detecting non-small cell lung cancer. Building on Dr. Ganepola's discovery of a biomarker for pancreatic cancer, the team combined with Wistar on the lung cancer study. The U.S. Preventive Services Task Force recommends an annual screening for patients 55 to 80 years old with a history of smoking and who are at high risk for developing lung cancer. Confirming the accuracy of the protein in a broader, more robust study could result in developing a simple blood test for annual screenings, rather than the less accurate, more expensive CT scan, which exposes patients to radiation.
According to the American Cancer Society (ACS), lung cancer is the second most common cancer in both men and women, accounting for about 13 percent of all new cancers. For 2015 ACS projects about 221,200 new cases of lung cancer and an estimated 158,040 deaths from lung cancer. Lung cancer accounts for about 27 percent of all cancer deaths and is by far the leading cause of cancer death among both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. Lung cancer mainly occurs in older people. About 2 out of 3 people diagnosed with lung cancer are 65 or older, with the average age at the time of diagnosis being about 70. Overall, the chance that a man will develop lung cancer in his lifetime is about 1 in 13; for a woman, the risk is about 1 in 16. These numbers include both smokers and non-smokers. For smokers the risk is much higher, while for non-smokers the risk is lower. Despite the very serious prognosis of lung cancer, some people with earlier stage cancers are cured. More than 430,000 people alive today have been diagnosed with lung cancer at some point (http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics).
According to Dr. Ganepola, "Cancer is a dreadful disease which kills more than half of patients. The other half survives for only one reason -- if the disease is detected early enough to be eradicated completely. This is only possible if you have a test that can detect cancer non-invasively early enough so patients can benefit from early, rather than late-stage treatment. If the tumors are detected early enough, the survival rate can dramatically improve."